Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06671756 · ClinicalTrials.gov registry record · NA

Metabolic Effects of Fructose Intake

A NA study, sponsored by Baylor College of Medicine.

Completed
Registry status
NA
Development phase
8
Enrollment target

NCT06671756: Completed NA study, sponsored by Baylor College of Medicine.

NCT06671756 is a NA study that has completed, run by Baylor College of Medicine. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06671756, a NA study, has completed, sponsored by Baylor College of Medicine.

COMPLETED
Registry status
NA
Development phase
8 participants
Enrollment target

Study Summary

The goal of this clinical trial is to learn how fructose ingestion affects metabolic factors in healthy adults aged 18-64, with a BMI between 19 and 30 kg/m², of any sex or gender. Specifically, the study aims to examine the impact of fructose compared to glucose on circulating metabolic factors including the soluble leptin receptor. The main questions it aims to answer are: How does fructose ingestion influence levels of circulating metabolic markers, including the soluble leptin receptor? Does fructose consumption have different metabolic effects compared to glucose? Participants will: Complete a screening phone call to review their health history and eligibility. Attend two in-person visits at least two weeks apart, where they will: Fast for 8 hours beforehand. Consume a beverage containing either 75g of fructose or glucose. Have blood drawn at regular intervals for up to 5 hours after consumption to measure circulating levels of metabolic markers.

Primary Outcome

The study will measure changes in the blood levels of soluble leptin receptor (ng/mL) following fructose ingestion. These levels will be assessed at multiple time points-baseline (0 minutes), 30 minutes, 60 minutes, 120 minutes, 180 minutes, 240 minutes, and 300 minutes post-ingestion-to evaluate how fructose affects their concentrations compared to baseline levels and glucose ingestion.

Interventions

  • DIETARY_SUPPLEMENT Fructose Ingestion
  • DIETARY_SUPPLEMENT Glucose Ingestion

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2024-12-02
Est. Completion 2025-05-31
Phase NA
Baylor College of Medicine

616 total trials

What the finished NCT06671756 record still lists

NCT06671756 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).

The record links to 0 conditions, and to 2 interventions - of which Fructose Ingestion is the first listed.

NCT06671756 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06671756 about?

NCT06671756 is a clinical study titled "Metabolic Effects of Fructose Intake". The goal of this clinical trial is to learn how fructose ingestion affects metabolic factors in healthy adults aged 18-64, with a BMI between 19 and 30 kg/m², of any sex or gender. Specifically, the study aims to examine the impact of fructose compared to glucose on circulating metabolic factors inc...

What is the current status of trial NCT06671756?

This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2024-12-02. Estimated completion is 2025-05-31.

What interventions are being tested in trial NCT06671756?

The interventions under investigation include: Fructose Ingestion (DIETARY_SUPPLEMENT), Glucose Ingestion (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT06671756?

This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT06671756's enrollment target sits among peer trials

8 1976th of 2000 higher than 19 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06671756, the US trial registry maintained by the National Library of Medicine. NCT06671756 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.